‘False Hopes' Dashed in Norway as Thousands Mistakenly Told of Lottery Wins
The company, Norsk Tipping, said that a coding error had led to notifications about 'erroneously high prizes' for Friday's EuroJackpot, a Europewide lottery. It said in a statement that 'several thousand' players had been affected, apologizing for the mistake.
'The error was discovered after a short time, but the damage was done,' Norsk Tipping said in a statement on Monday that noted the departure of its chief executive.
Before leaving the company, the chief executive, Tonje Sagstuen, had apologized for giving people 'false hopes.'
'We understand of course that this is a breach of trust,' she said of the error, noting that she had received messages from players who had started to plan vacations or buy a home.
Norsk Tipping, which handles the notifications for EuroJackpot in Norway, said that it received prize amounts in euros and then converted the figures to Norwegian kroner. The issue came from what Norsk Tipping described as a 'manual error' in the conversion code: Instead of dividing amounts by 100, as intended, the code multiplied them by 100, it said in a separate statement.
EuroJackpot did not immediately respond to a request for comment. According to figures on the lottery's website, the total prize fund for Friday's draw was about $50 million.
Norsk Tipping did not specify how many customers had been affected by the error or how much they had been told they had won. The company did not immediately respond to a request for further comment.
Sylvia Brustad, the chairwoman of Norsk Tipping, acknowledged that 'trust has been broken,' and said the company, which has come under heavy criticism from customers and the government, would work to do better.
'We are determined to clean up and improve ourselves,' she said.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Forbes
an hour ago
- Forbes
Powerball Jackpot Hits $426 Million—Here's How Much the Winner Could Take Home After Taxes
The Powerball jackpot ticked up to $426 million after no winners were drawn Saturday night, but a lucky winner or winners would take home substantially less after paying federal and state taxes on their winnings. Winners from Monday's upcoming drawing could get either $426 million in installments or a lump sum of $193.5 million, but that would get slashed significantly after taxes. Getty Images No tickets were sold matching all of Saturday's numbers (6, 18, 34, 35, 36, and Powerball number 2), raising the jackpot again for Monday's upcoming drawing. If a winner is drawn Monday, they will have the option of either accepting the $426 million prize spread out over 30 annualized payments, or take the lump sum of $193.5 million, which is the more popular option for winners. However, a federal withholding tax of 24% is applied to that jackpot, bringing the winnings down to $323.7 million, or $147 million for the lump sum. The winnings are then taxed based on the winners income—which could rise as high as 37% for Americans in the highest tax bracket, bringing the final winnings for the lump sum down to $121.9 million. State taxes then reduce this jackpot even further, with New York charging the highest rate at 10.9%, though some states, including California, Florida and Texas, do not tax winnings. The next drawing is scheduled for Monday night at 10:59 p.m. EDT. If no winner is drawn Monday, the next drawings will take place Wednesday and Saturday. Key Background The odds for winning the Powerball jackpot are 1 in 292.2 million, according to the lottery organizers. The odds of winning the $1 million prize (with a ticket matching five numbers without the Powerball number) are 1 in 11.6 million. Big Number $526 million. That's how much a lucky winner in California got after purchasing a winning ticket in March. Because that player won in the Golden State, they did not have to pay state taxes on those winnings.
Yahoo
3 hours ago
- Yahoo
Denmark's Economy Runs on Novo. Will the Drugmaker's Troubles Slim It Down?
(Bloomberg) -- Denmark's status as one of the few countries in Europe with an expanding economy rests in part on the success of its homegrown hero, Novo Nordisk A/S. Thanks to the pharmaceutical giant's astronomical rise, the country enjoyed growth of 3.5% last year, outpacing most nations in the region. But after a series of stumbles, Novo is struggling to retain its edge in the cutthroat US weight-loss market. The World's Data Center Capital Has Residents Surrounded An Abandoned Art-Deco Landmark in Buffalo Awaits Revival We Should All Be Biking Along the Beach Seeking Relief From Heat and Smog, Cities Follow the Wind NYC Mayor Adams Gives Bally's Bronx Casino Plan a Second Chance That, in turn, is generating concern about whether the company's troubles could lead to mass layoffs or become a drag on the broader Danish economy. Novo's market value shrunk by almost $100 billion this week after the company cut its profit outlook on Tuesday, citing intensifying competition and copycat drugs in the US. It marked the second time this year that the drugmaker pared back its earning projections. Shares plunged 23% — the steepest single-day drop on record — and its stock has continued to slide in the days since. Novo's bad news translated into an immediate financial blow to Danish households. Outside of pension savings, Danes lost 38 billion kroner ($5.8 billion) in regular stock portfolios on Tuesday alone, according to estimates by Sydbank A/S. That's the equivalent of almost 3% of total annual private consumption. 'There will be shareholders who have lost rather large amounts,' said Mikael Bak, chief executive officer of the Danish Shareholders' Association. 'It's quite conceivable that we'll see some Danish investors holding back on things like buying a new car or booking an expensive vacation.' Given Novo's size, the damage could ripple beyond the stock market. Economists have warned that a prolonged Novo slump could drag on the country's exports — a concern shared by the state's financial watchdog, which slashed its export forecast in May following a profit warning from Novo — and even influence interest rates. Moreover, since the drugmaker's production counts toward Denmark's gross domestic product, any roll-back of expectations will 'almost mechanically' impact the country's growth numbers, said Las Olsen, chief economist at Danske Bank A/S, Denmark's largest lender. 'Lower growth in Novo means lower GDP growth in Denmark, it's as simple as that,' said Olsen. A decline in drug sales did cause the Danish economy to shrink slightly in the first quarter, according to Statistics Denmark, and second-quarter GDP numbers will be released on Aug. 20. Novo is still growing, Olsen stressed, but if it were to flatline completely, Denmark would cease to be among Europe's highest growth economies. Soren Kristensen, chief economist at Sydbank, cautioned against reading too deeply into Novo's dip. Analysts predict the company's revenue and profit growth will continue through the end of the decade, and Kristensen emphasized that so long as the firm's earnings are increasing, the Danish economy will benefit. Still, he added, Novo is 'in a slightly more vulnerable position' than previously assumed. 'If things were to take a turn for the worse,' he said, 'the effects would show up in quite a few areas.' He pointed to the country's industrial production and exports as most exposed. Novo's vast output has helped drive Denmark's large surplus and bolstered the krone. That has made it necessary for the Danish central bank to maintain a lower interest rate than the European Central Bank's to defend the currency peg. Should exports take a major hit, however, Kristensen said that Denmark might need to reverse course and raise its rates. Within Denmark, a sustained Novo slowdown could also limit funding increases in scientific research, healthcare and social programs, Olsen said. That's because the Novo Nordisk Foundation, which owns a controlling stake in the company, has significantly ramped up its grantmaking in these areas on the back of soaring profits from blockbuster drugs Wegovy and Ozempic. The foundation supports the work and salaries of around 9,500 scientists. Novo's rise in recent years has fueled broader concern about Denmark becoming overly reliant on a single company. To those worried about the drugmaker's outsized role in the country, its setbacks this week evoked specters of Nokia Oyj, the Finnish telecommunications giant whose slump in the early 2000s dragged down Finland's entire economy. Denmark's Prime Minister Mette Frederiksen admitted in an interview last year that officials need to keep an eye on the risks linked to Novo's dominant position, but brushed off Nokia comparisons, noting that the economy's strengths aren't concentrated in the pharmaceutical sector alone. Olsen from Danske Bank takes a similar view. He noted that Novo is still growing, while Nokia underwent a serious contraction, and argued that even if Novo were to experience a similar downturn, Denmark's economy would be better positioned to absorb the shock. For all its growth, he said, the drugmaker has a limited impact on national employment and wages — both of which remain resilient — and the Danish economy is more flexible on account of its adaptive wage structures and rules that make it easier to fire employees. Denmark also relies on large inflows of foreign labor to meet workforce needs, which can be adjusted as needed. Still, the company directly employs more than 30,000 people in Denmark. If layoffs are in the offing, as new CEO Maziar Mike Doustdar has hinted, key Novo hubs such as Kalundborg and Bagsvaerd are likely to take a hit. Outside of the agricultural industry, Novo was responsible for half of all private-sector job growth in Denmark between early 2023 and 2024, according to the state's fiscal watchdog. 'Locally, it could feel quite severe, even if it doesn't show up strongly in national figures,' Kristensen said, especially as cuts and investment reductions are likely to reverberate through Novo's network of suppliers and contractors. Nowhere in Denmark have Novo's rising fortunes registered more strongly than in Kalundborg, home to the company's main production facilities. As corporate tax revenue from Novo has surged more than tenfold since 2011, unemployment has dropped to record lows and the town has experienced a boom. Novo's factory expansions and rapid hiring have bolstered local businesses, universities and research programs have flocked to the town, and investment is flowing into housing and infrastructure. 'What's been the impact of the massive growth in Novo Nordisk?' Olsen said. 'It's delivered GDP growth, shareholder returns, extra tax revenue and a current account surplus. So if the situation were to go the other way, all of those effects would naturally reverse.' How Podcast-Obsessed Tech Investors Made a New Media Industry Everyone Loves to Hate Wind Power. Scotland Found a Way to Make It Pay Off Russia Builds a New Web Around Kremlin's Handpicked Super App Cage-Free Eggs Are Booming in the US, Despite Cost and Trump's Efforts What's Really Behind Those Rosy GDP Numbers? ©2025 Bloomberg L.P. Sign in to access your portfolio
Yahoo
7 hours ago
- Yahoo
Innovation, International Growth, and Strong Financials Drive Microvast Holdings, Inc. (MVST)'s Future Growth
With a low price-to-earnings multiple and strong hedge fund interest, Microvast Holdings, Inc. (NASDAQ:MVST) earns a spot on our list of the . A person inspecting a lithium-ion battery that is being recycled. Innovation, international growth, and strong financials are helping Microvast Holdings, Inc. (NASDAQ:MVST) become a significant player in the battery technology industry. Through a collaboration with Norway's Evoy, Microvast Holdings, Inc. (NASDAQ:MVST) entered the marine electrification market in 2024 by incorporating its MV-I battery into high-output electric boats, which served as a gateway to specialist industries like aviation and defense. The momentum continued in January 2025 when Microvast Holdings, Inc. (NASDAQ:MVST) unveiled a breakthrough in True All-Solid-State Battery technology, offering enhanced safety and performance. Citing Microvast's remarkable Q1 2025 results—a 43.2% YoY sales spike, a $61.8 million profit, and growing demand from the EMEA region—H.C. Wainwright reiterated a Buy rating on May 13. A few days later, on May 19, Microvast Holdings, Inc. (NASDAQ:MVST) demonstrated its innovative edge by showcasing its newest high-energy and fast-charging batteries at the China International Battery Fair. Looking ahead, the company is in an excellent position for future growth, as seen by its shares rising 694% in the last year. Microvast Holdings, Inc. (NASDAQ:MVST) provides solid-state energy storage and battery solutions for EVs, making it a compelling low-cost investment in the sector. It is included in our list of cheap solid state battery stocks. While we acknowledge the potential of MVST as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 14 Cheap Transportation Stocks to Buy According to Analysts and 10 Cheap Lithium Stocks to Buy According to Hedge Funds. Disclosure: None.
